Current Assets
Available-for-Sale Debt Securities - Amortized Cost (Due Within One Year)
Moderna Available-for-Sale Debt Securities - Amortized Cost (Due Within One Year) increased by 3.1% to $3.3B in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 24.2%, from $4.35B to $3.3B. Over 5 years (FY 2020 to FY 2025), Available-for-Sale Debt Securities - Amortized Cost (Due Within One Year) shows an upward trend with a 10.1% CAGR.
Analysis
StatementBalance Sheet Statement
SectionCurrent Assets
First reportedQ1 2018
Last reportedQ1 2026May 1, 2026
Metric ID:
afs_debt_securities_amortized_cost_1yHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $2.39B | $3.36B | $3.88B | $5.09B | $5.08B | $5.42B | $6.79B | $5.58B | $4.75B | $4.72B | $5.75B | $6.54B | $6.07B | $5.24B | $5.11B | $4.35B | $3.85B | $3.37B | $3.2B | $3.3B |
| QoQ Change | — | +40.7% | +15.7% | +31.2% | -0.3% | +6.7% | +25.4% | -17.9% | -14.8% | -0.7% | +21.8% | +13.6% | -7.2% | -13.6% | -2.6% | -14.8% | -11.5% | -12.5% | -5.1% | +3.1% |
| YoY Change | — | — | — | — | +112.9% | +61.4% | +75.0% | +9.4% | -6.5% | -12.9% | -15.3% | +17.2% | +27.7% | +11.0% | -11.2% | -33.4% | -36.5% | -35.7% | -37.3% | -24.2% |
Range$2.39B – $6.79B
CAGR+7.0%
Avg YoY Growth+6.3%
Median YoY Growth-8.8%
Available-for-Sale Debt Securities - Amortized Cost (Due Within One Year) at Other Companies
Frequently Asked Questions
- What is Moderna's available-for-sale debt securities - amortized cost (due within one year)?
- Moderna (MRNA) reported available-for-sale debt securities - amortized cost (due within one year) of $3.3B in Q1 2026.
- How has Moderna's available-for-sale debt securities - amortized cost (due within one year) changed year-over-year?
- Moderna's available-for-sale debt securities - amortized cost (due within one year) decreased by 24.2% year-over-year, from $4.35B to $3.3B.
- What is the long-term trend for Moderna's available-for-sale debt securities - amortized cost (due within one year)?
- Over 5 years (2020 to 2025), Moderna's available-for-sale debt securities - amortized cost (due within one year) has grown at a 10.1% compound annual growth rate (CAGR), from $1.98B to $3.2B.